Update MRONJ and perspectives of its treatment
Update MRONJ and perspectives of its treatment
复制标题
DOI：
10.1016/j.jormas.2017.06.012
复制
发表时间：
2017-09-01
影响因子：
2.2
通讯作者：
Semper-Hogg, W.
中科院分区：
文献类型：
--
作者：
Voss, P. J.;Poxleitner, P.;Semper-Hogg, W.
抗骨吸收剂广泛应用于分解代谢性骨病。不仅双膦酸盐，而且像狄诺塞麦这样的新药也可能引起颌骨骨坏死作为副作用。本文综述了目前常用的抗骨吸收药物的作用机制、抗骨吸收药物相关性颌骨骨坏死（ARONJ）的发病机制及潜在的危险因素。此外，诊断模式和治疗方案，以及新的和创新的战略进行了讨论。避免ARONJ发生的主要关键因素仍然是实施全面的预防措施。(C)2017 Elsevier Masson SAS。All rights reserved.
Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures. (C) 2017 Elsevier Masson SAS. All rights reserved.